Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.37 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036160 | 1.00 | DPP4 (0.50) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL1036159 | 1.00 | DPP4 (0.50) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL1521317 | 0.92 | DPP4 (0.44) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL1521228 | 0.92 | DPP4 (0.44) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL1521315 | 0.92 | DPP4 (0.44) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL1521233 | 0.92 | DPP4 (0.44) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL8586463 | 0.87 | DPP4 (0.40) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL8586461 | 0.87 | DPP4 (0.40) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL1034774 | 0.82 | DPP4 (0.53) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL1034776 | 0.82 | DPP4 (0.53) | DPP4DPP8DPP7FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004031142-A2 | INHIBITION OF METALLO-BETA-LACTAMASE | TEXAS TECH UNIVERSITY SYSTEM (US) | 2004-04-15 | — | — | WO | claimed |
| US-20240139282-A1 | LIQUID DALBAVANCIN COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024079224-A1 | LIQUID DALBAVANCIN COMPOSITION | XELLIA PHARMACEUTICALS APS (DK) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024079223-A1 | LIQUID DALBAVANCIN COMPOSITION | XELLIA PHARMACEUTICALS APS (DK) | 2024-04-18 | — | — | WO | disclosed |
| US-20240083950-A1 | SYNTHESIS PROCESS | XELLIA PHARMACEUTICALS APS (DK) | 2024-03-14 | — | — | US | disclosed |
| EP-4274842-A1 | SYNTHESIS PROCESS | Xellia Pharmaceuticals ApS (DK) | 2023-11-15 | — | — | EP | disclosed |
| CN-116710470-A | Synthesis method | 埃克斯利亚制药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022148868-A1 | SYNTHESIS PROCESS | XELLIA PHARMACEUTICALS APS (DK) | 2022-07-14 | — | — | WO | disclosed |
| CN-104807760-A | Universal type multi-signal output biosensor, as well as preparation method and application thereof | UNIV LUDONG | 2015-07-29 | — | — | CN | disclosed |
| US-20090203003-A1 | INHIBITION OF METALLO-BETA-LACTAMASE | TEXAS TECH UNIVERSITY SYSTEM (US) | 2009-08-13 | — | — | US | disclosed |
| US-4560508-A | BETA-LACTAMASE INHIBITORS, ANINICROBIAL AGENT, CHEMICAL INTERMEDIATE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-12-24 | — | — | US | disclosed |
| US-4550105-A | BETA-LACTAMASE INHIBITORS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-29 | — | — | US | disclosed |
| EP-0021678-B1 | 1-SULPHO-2-OXOAZETIDINE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1984-11-07 | — | — | EP | disclosed |
| EP-0095764-A2 | 2-Oxoazetidinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-12-07 | — | — | EP | disclosed |
| US-4416817-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-11-22 | — | — | US | disclosed |
| EP-0083039-A1 | 4-Cyano-2-azetidinones and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1983-07-06 | — | — | EP | disclosed |
| EP-0053815-A1 | 2-Oxoazetidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
| EP-0053387-A1 | Method of preparing 1-sulfo-2-oxoazetidine derivatives and intermediates therefor | Takeda Chemical Industries, Ltd. (JP) | 1982-06-09 | — | — | EP | disclosed |
| EP-0021676-A1 | 3-Methoxy-2-oxoazetidine derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1981-01-07 | — | — | EP | disclosed |
| EP-0021678-A1 | 1-Sulpho-2-oxoazetidine derivatives, their production and pharmaceutical compositions thereof | Takeda Chemical Industries, Ltd. (JP) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139282-A1 | LIQUID DALBAVANCIN COMPOSITIONS | STT3B, DDOST, KRTCAP2 | DPP4 590/4885DPP8 1223/4885DPP7 759/4885 |
| US-20240083950-A1 | SYNTHESIS PROCESS | AS3MT, O60361, TPD52L2 | DPP4 271/4885DPP8 604/4885DPP7 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.